Galectin Therapeutics Releases Richard E. Uihlein’s Open Letter to Stockholders Dated May 10, 2019 Read more about Galectin Therapeutics Releases Richard E. Uihlein’s Open Letter to Stockholders Dated May 10, 2019
Galectin Therapeutics Reports Q1 2019 Financial Results and Provides Business Update Read more about Galectin Therapeutics Reports Q1 2019 Financial Results and Provides Business Update
Galectin Therapeutics Inc. Announces Record Date, Subscription Pricing, and Expiration Date for Rights Offering and Effectiveness of its Registration Statement Read more about Galectin Therapeutics Inc. Announces Record Date, Subscription Pricing, and Expiration Date for Rights Offering and Effectiveness of its Registration Statement
Galectin Therapeutics to Present at the 2019 H.C. Wainwright Global Life Sciences Conference Read more about Galectin Therapeutics to Present at the 2019 H.C. Wainwright Global Life Sciences Conference
Providence Cancer Institute to Present Findings on GR-MD-02 at the 2019 Keystone Symposia on Molecular and Cellular Biology Read more about Providence Cancer Institute to Present Findings on GR-MD-02 at the 2019 Keystone Symposia on Molecular and Cellular Biology
Galectin Therapeutics Releases Richard E. Uihlein’s Open Letter to Stockholders Read more about Galectin Therapeutics Releases Richard E. Uihlein’s Open Letter to Stockholders
Galectin Therapeutics Files Registration Statement for Stockholder Rights Offering of Common Stock and Warrants Read more about Galectin Therapeutics Files Registration Statement for Stockholder Rights Offering of Common Stock and Warrants
Galectin Therapeutics Reports Fiscal 2018 Financial Results and Provides Business Update Read more about Galectin Therapeutics Reports Fiscal 2018 Financial Results and Provides Business Update
Galectin Therapeutics to Present at Berenberg NASH Day in New York Read more about Galectin Therapeutics to Present at Berenberg NASH Day in New York
Galectin Therapeutics’ Largest Institutional Shareholder Converts Existing Series B Preferred Stock Into Common Stock Streamlining Its Capital Structure Read more about Galectin Therapeutics’ Largest Institutional Shareholder Converts Existing Series B Preferred Stock Into Common Stock Streamlining Its Capital Structure